A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
A study by Canadian researchers shows that preventive oophorectomy reduces risk of ovarian, fallopian tube, or peritoneal cancer by 80% in women who have BRCA1 or BRCA2 mutations. Published in The Journal of Clinical Oncology, the report also documented a 77% reduction in all-cause mortality.
An international registry was used to identify 5783 women with a BRCA1 or BRCA2 mutation, who then completed a baseline questionnaire and at least one follow-up questionnaire. The participants were observed until they were diagnosed with ovarian, fallopian, or peritoneal cancer, death, or date of most recent follow-up. The goal was to assess the impact of prophylactic oophorectomy on all-cause mortality and estimate 5-year survival associated with clinically detected ovarian, occult, and peritoneal cancers diagnosed in the cohort.
After average follow up of 5.6 years, a total 186 women developed ovarian (n=132), fallopian (n=22), or peritoneal (32) cancer, 68 of whom have died. Bilateral oophorectomy was associated with a hazard ratio (HR) for ovarian, fallopian, or peritoneal cancer of 0.20 (95% CI, 0.13 to 0.30; P< .001). The HR for all-cause mortality at age 70 years associated with oophorectomy was 0.23 (95% CI, 0.13 to 0.39; P< .001) for women who had no history of cancer at baseline.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Diabetes linked to altered long-term inflammatory response in mesh implantation
July 15th 2024A recent study highlights the association between diabetes and complications from urogynecologic mesh implants, emphasizing the need for further research on glycemic control in affected patients.
Read More